Status:
COMPLETED
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
Lead Sponsor:
BioWest Therapeutics Inc
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 w...
Eligibility Criteria
Inclusion
- Patients who completed HCV-05-002 only
- 18-65 years of age, inclusive
- Primary diagnosis of chronic HCV infection
- Non-responders to previous pegylated interferon-based therapy
Exclusion
- Patients naive to interferon-based therapy for chronic HCV infection
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00292084
Start Date
February 1 2006
End Date
October 1 2007
Last Update
January 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Halifax, Nova Scotia, Canada